Jenkem Technology stated on the interactive platform that the current clinical indications for the company's self-developed project, injectable polyethylene glycol iltercan, are small cell lung cancer and glioblastoma. Among them, the indication for the treatment of glioblastoma with injectable polyethylene glycol iltercan is still in phase 2 enrollment.
键凯科技：注射用聚乙二醇伊立替康治疗脑胶质瘤适应症仍在二期入组阶段
Jenkem Technology: The indication for the treatment of glioblastoma with injectable polyethylene glycol iltercan is still in phase 2 enrollment.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated